SGX94: Completed Phase II enrollment

Soligenix completed enrollment of about 95 patients undergoing chemoradiation therapy for head and neck cancer in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 1.5, 3 and 6 mg/kg ...